Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.32 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.31 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17839932 | 0.87 | NR1H4 (0.41) | NR1H4MAPK14ALDH1A1NPC1RAB9A | |
| SCHEMBL1095874 | 0.86 | NR1H4 (0.42) | NR1H4MAPK14ALDH1A1NPC1RAB9A | |
| SCHEMBL20833733 | 0.86 | NR1H4 (0.40) | NR1H4MAPK14ALDH1A1NPC1RAB9A | |
| SCHEMBL2772447 | 0.81 | NR1H4 (0.39) | NR1H4MAPK14ALDH1A1NPC1RAB9A | |
| SCHEMBL22392553 | 0.80 | NR1H4 (0.41) | NR1H4MAPK14ALDH1A1NPC1RAB9A | |
| SCHEMBL28410381 | 0.79 | NR1H4 (0.44) | NR1H4MAPK14ALDH1A1NPC1RAB9A | |
| SCHEMBL20833739 | 0.79 | NR1H4 (0.42) | NR1H4MAPK14GRM2DHODH | |
| SCHEMBL20833799 | 0.79 | NR1H4 (0.36) | NR1H4ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30807047 | 0.79 | NR1H4 (0.36) | NR1H4ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20833800 | 0.78 | NR1H4 (0.36) | NR1H4ALDH1A1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111511731-B | Olefin compounds as modulators of the farnesol X receptor | 百时美施贵宝公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-111278817-B | Polycyclic compounds as farnesol X receptor modulators | 百时美施贵宝公司 | 2023-05-16 | — | — | CN | disclosed |
| EP-3704106-B1 | ALKENE COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-04-12 | — | — | EP | disclosed |
| EP-3704107-B1 | MULTICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-04-12 | — | — | EP | disclosed |
| US-11370785-B2 | Multicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-06-28 | — | — | US | disclosed |
| US-11370785-B2 | Multicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-06-28 | — | — | US | disclosed |
| US-20210380578-A1 | MULTICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2021-12-09 | — | — | US | disclosed |
| US-20210380578-A1 | MULTICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2021-12-09 | — | — | US | disclosed |
| US-11168079-B2 | Alkene compounds as farnesoid x receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-09 | — | — | US | disclosed |
| US-11168079-B2 | Alkene compounds as farnesoid x receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-09 | — | — | US | disclosed |
| US-20160176861-A1 | HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2016-06-23 | — | — | US | disclosed |
| US-20160176861-A1 | HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2016-06-23 | — | — | US | disclosed |
| US-20160176861-A1 | HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2016-06-23 | — | — | US | disclosed |
| WO-2016096115-A1 | HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016096115-A1 | HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-8153624-B2 | Compounds and methods for modulating FXR | ELI LILLY AND COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| EP-2178851-B1 | COMPOUNDS AND METHODS FOR MODULATING FXR | LILLY CO ELI (US) | 2011-12-28 | — | — | EP | disclosed |
| US-20100152166-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2010-06-17 | — | — | US | disclosed |
| EP-2178851-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | Eli Lilly & Company (US) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009012125-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11370785-B2 | Multicyclic compounds as farnesoid X receptor modulators | NR1H4, FXR1, GPBAR1 | NR1H4 1/4885MAPK14 1548/4885ALDH1A1 2905/4885 |
| US-20210380578-A1 | MULTICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | NR1H4, FXR1, GPBAR1 | NR1H4 1/4885MAPK14 1548/4885ALDH1A1 2905/4885 |
| US-20100152166-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, FXR1, SLC10A1 | NR1H4 1/4885MAPK14 2336/4885ALDH1A1 2124/4885 |
| US-11168079-B2 | Alkene compounds as farnesoid x receptor modulators | FXR1, NR1H2, NR1H4 | NR1H4 3/4885MAPK14 1714/4885ALDH1A1 2224/4885 |
| US-20160176861-A1 | HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H3, NR1H2 | NR1H4 1/4885MAPK14 2499/4885ALDH1A1 2674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.